曲前列尼尔治疗肺动脉高压临床疗效的系统评价.PDF

Review Articles Chin J Evid-based Med 2016, 16(2): 212-218 1 2 3 1. 7300002. 730000 3. 730000 PubMedEMbase The Cochrane Library 2015 2 CBMWanFang Data CNKI RCT2015 5 1 2 RevMan 5.3 Meta 7 RCT1 662 Meta 6 MD=19.6295%CI 0.55 38.69P=0.04Brog MD= 0.5295%CI 0.960.07P=0.02MD=0.19 95%CI 0.080.30P=0.000 6MD= 3.2395%CI 4.801.66P0.000 1 Meta Clinical Ef ects of Treprostinil for Pulmonary Arterial Hypertension: A Systematic Review 1 2 3 ZHAO Hong-lin , YAO Liang , ZHANG Xin-dao 1. Department of Cardiovascular Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China; 2. School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China; 3. Department of Pediatrics, the First Hospital of Lanzhou University, Lanzhou 730000, China Abstract Objective To systematically review the efficacy and safety of treprostinil for patients with pulmonary arterial hypertension (PAH). Methods Databases including PubMed, EMbase, The Cochrane Library (Issue 2, 2015), WanFang Data, CBM and CNKI were searched to collect randomized controlled trials (RCTs) about treprostinil for PAH from inception to 1st May 2015. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results A total of seven RCTs including 1 662 participants were finally included. The results of meta-analysis showed that, compared with placebo, treprostinil could increase patients’ 6-min walk distance (MD=19.62, 95%CI 0.55 to 38.69, P=0.63), reduce Brog score (MD= 0.52, 95%CI 0.96 to 0.07, P=0.06), decrease pulmonary vascular resistance (MD=-3.23, 95%CI 4.80 to 1.66, P=0.42) and improve cardiac index (MD=0.19, 95%CI 0